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Background: Poor prognosis of medullary thyroid cancer (MTC) with suspicious ultrasound (US) features has been
reported. The aim of the study was to investigate the association between preoperative US presentation and
aggressiveness features of MTC. Also, US features of MTC were compared with those previously reported.
Methods: Study group comprised 134 MTC from nine different centers. Based on US presentation the nodules
were stratified in “at risk for malignancy” (m-MTC) or “probably benign” (b-MTC) lesions.
Results: Eighty nine (66.4%) m-MTC and 45 (33.6%) b-MTC were found. Metastatic lymph nodes (p = 0.0001) and
extrathyroid invasiveness (p < 0.0001) were more frequent in m-MTC. There was statistically significant correlation
(p = 0.0002) between advanced TNM stage and m-MTC with an Odds Ratio 5.5 (95% CI 2.1–14.4). Mean postsurgical
calcitonin values were 224 ± 64 pg/ml in m-MTC and 51 ± 21 in b-MTC (p = 0.003).
Conclusions: This study showed that sonographically suspicious MTC is frequently associated with features of
aggressiveness, suggesting that careful preoperative US of MTC patients may better plan their surgical approach.
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Medullary thyroid cancer (MTC) originates from thyroid C
cells and accounts for about 5% of thyroid malignancy [1].
MTC may occur as sporadic tumor (about 80% of cases) or
be part of a familial disorder [1]. The diagnosis of MTC rep-
resents a diagnostic challenge in clinical practice. Fine needle
aspiration (FNA) of thyroid nodules has several pitfalls for
this histologic type. The cytologic examination can diagnose
MTC with classical presentation, and the detection rate was
reported of 56% in a recent meta-analysis [2]. The routine
measurement of serum calcitonin is still a matter of debate
and ultrasonography (US) does not achieve high reliability* Correspondence: pierpaolo.trimboli@gmail.com
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unless otherwise stated.rates [3]. Due to these limitations, many MTC are still inci-
dentally discovered after thyroid excision, leading to the risk
of an incomplete therapeutic approach and thus of a poorer
prognosis [4]. To diagnose MTC prior to surgery is of high
importance. This allows to examine other disorders poten-
tially associated with hereditary forms of MTC and in-
creases the possibility to achieve a complete surgical cure.
Therefore, a carefully planned initial surgical treatment of
patients with the preoperative diagnosis of MTC is strongly
required [1].
Ultrasound examination is the pivotal imaging tool in the
risk stratification of thyroid nodules. It allows the identifi-
cation of non palpable nodules and the assessment of their
characteristics. Several papers have reported the presence
of specific US features as highly suggestive of malignancy
[1,5]. Moreover, preoperative neck US evaluation is the gold
standard in the surgical planning of patients undergoingl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinical characteristics of the study group
Age of patients (years)* 56.7 ± 1.2
Preoperative calcitonin (pg/ml)* 558 ± 62
Postoperative calcitonin (pg/ml)* 167 ± 44
Nodule’s size (mm)* 19.8 ± 1.0
C cell hyperplasia (number of patients/total) 6/134
MEN 2 (number of patients/total) 2/134
Hereditary cancer (number of patients/total) 14/134
Single nodule (number of patients/total) 72/134
Footnote: *Mean values ± Standard Deviation.






pN1 status 43 (48.3%) 5 (11.1%) 0.0001
Extrathyroid tumor extension 27 (30.3%) 1 (2.2%) <0.0001
RET mutation 12 (13.4%) 2 (4.4%) 0.13
C cell hyperplasia 6 (6.7%) 0 0.09
Multifocal lesions 11 (12.3%) 1 (2.2%) 0.06
Associated MEN-2 2 (2.2%) 0 0.55
Presence of >1 of
the above parameters
61 (68.5%) 8 (17.8%) <0.0001
Detectable postoperative serum CT 42.2% 20% 0.04
Abbreviations: pN1 status: neck lymph node involvement, MEN: multiple
endocrine neoplasia, m-MTC: medullary thyroid cancer with “malignant” US
appearance; b-MTC: medullary thyroid cancer with “benign or indeterminate”
US appearance.
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the US features of differentiated papillary thyroid carcin-
oma (PTC), and only limited data are available regarding
the US criteria for possibly malignant MTCs, and the
possible association between US features of MTCs and
cancer aggressiveness [6-12].
The aim of this study was investigate the aggressiveness
features of MTC in association with their preoperative US
presentation. The US features of MTC in comparison to
those reported in the literature are also described.
Materials and methods
This multicenter retrospective study included patients who
had been diagnosed and operated for MTC over the period
from March 2007 to March 2013 at nine different centers.
The preoperative diagnosis had been based on high serum
calcitonin levels with a suggestive cytology and/or detection
of calcitonin in fine needle aspiration washout [13-15]. All
patients had undergone total thyroidectomy with central
nodal neck dissection in all cases. Patients with suspicious
neck lymph nodes on preoperative imaging had undergone
lateral neck dissection. In all patients the diagnosis of
MTC was confirmed by histology according to the WHO
classification criteria [16]. Tumour staging was based on
the TNM classification [17]. Postoperative parameters that
could be associated with aggressiveness including the
presence of lymph node involvement (pN1), extrathyroid
tumor extension, RET mutation, multifocality of lesions,
concomitant C cell hyperplasia and MEN 2 were recorded
by reviewing the patients files.
The US appearance of the lesions was assessed by
retrieving and reviewing the preoperative thyroid and neck
US images in the institution PACS systems. In order to as-
sess the risk of malignancy by US, all nodules were assessed
by four reviewers with more than ten years experience in
thyroid US (PT, ES, VC, LuGi) according to a previously
described validated classification system. This classification
system stratifies nodules in classes 1 to 5 with intermediate
steps of 0.5 for classes 2 to 5 and nodules with category 3.5
or greater are regarded as probably malignant with a posi-
tive predictive value of 97% [18,19]. Briefly, class 1 includes
round or oval anechoic lesion, in class 2 there are regular-
shaped nodules with cystic change, class 3 contains solid
and regular-shaped nodule, class 4 comprises solid and
regular-shaped nodule, while solid and irregular-shaped
nodules with extrathyroid extension are in class 5. Based
on this system nodules with class ≥3.5 were categorized as
“malignant” (m-MTC) and nodules with class <3.5 as
“indeterminate or benign” (b-MTC). Discordant cases of
the present study were categorized by the examiners in
consensus. In case of multifocal MTC, only the most
prominent focus was analyzed in the study.
Statistical analysis was performed using standard statistical
software using Graph Pad Prism (Graph Pad Software Inc,La Jolla, CA, USA). Differences in frequencies were ana-
lyzed by chi-square test or Fisher exact test and differences
in mean values were evaluated using t-test. Statistical signifi-
cance was set at p < 0.05. Means and standard errors were
compared using Mann-Whitney test. The association of
suspicious US features of MTC with TNM stages was
analyzed using Odds Ratio (OR).Results
The study group consisted of 134 patients (85 females, 49
males, mean age 56.7 ± 1.2 years) with histologically
proved MTC. In 10.4% of cases there was a familial MTC.
Tumors were unifocal in 122/134 (91%) patients and
multifocal in 12/134 [9]. Concomitant C cell hyperplasia
was found in 6/134 (4.5%) cases and MEN 2 in 2/134
(1.5%) patients. The clinical, biochemical and histologic
characteristics of the study group are displayed in Table 1.
Based on the US criteria for risk evaluation, 89/134
(66.4%) were classified as m-MTC and 45/134 (33.6%) as
b-MTC. There was no statistically significant difference
between the two groups regarding the lesion size (m-MTC,
19.7 ± 1.3 mm; b-MTC, 20.1 ± 1.7, t-test p = 0.13) and
patients’ age (m-MTC, 56.9 ± 1.5 years; b-MTC, 56.6 ±
2.4 years, t-test p = 0.37).
Figure 1 TNM 2010 staging (17) of 134 histologically proved
medullary thyroid cancers with “malignant” (m-MTC) or
“benign or indeterminate” (b-MTC) ultrasound presentation.
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extrathyroid tumor extension (p < 0.0001) were signifi-
cantly more frequent in m-MTC than in b-MTC (Table 2).
Concomitant C cell hyperplasia and MEN 2 were
recorded only in m-MTC. More than one preoperative
parameter of tumor aggressiveness was significantly more
present m-MTCs than b-MTC (p < 0.0001) (Table 2).
Advanced TNM stage (III-IV) was significantly (p < 0.0001)
more frequent in m-MTC (48 cases, 53.9%) than in
b-MTC (6 cases, 13.3%). Suspicious US appearance
(m-MTC) was significantly (p = 0.0002) associated with
TNM stages III-IV with an OR of 5.5 (95% CI 2.1–14.4)
(Figure 1).
Preoperative serum calcitonin levels were available in 117
cases. Significant difference in mean preoperative calcitonin
levels was found (595 ± 76 pg/ml in m-MTC, 484 ± 106 pg/
ml in b-MTC p = 0.0001). Mean postoperative calcitonin
value was available in 106 patients, 30/71 (42.2%) m-MTC
and 7/35 (20%) b-MTC cases had detectable calcitonin.Figure 2 Different ultrasound presentations of MTC. (A) hypoechoic no
(B) mixed-spongiform nodule with hypoechoic halo, non-suspicious at ultrMean postoperative calcitonin value was significantly
(p = 0.003) higher in the m-MTC group (224 ± 64 pg/
ml) compared to b-MTC group (51 ± 21 pg/ml).
Discussion
In the last decade, high resolution US has been widely avail-
able and this contributed to an increase in the diagnosis of
thyroid malignancy [20,21]. The presence of specific US
features has been closely associated with higher risk for
malignancy [22]. Most of the US data in the literature
concern the papillary thyroid cancers, because of its higher
frequency among thyroid malignancies (about 80%) [20,21],
whereas limited and discordant data are available about the
US characteristics of medullary carcinomas [6-11].
The aim of this study was to investigate the association
between the features suggesting MTC aggressiveness and
its preoperative US features by reviewing the MTC cases
diagnosed in nine different centers over the last six years.
An amount of 66% of MTC could be classified as “at-risk”
by ultrasound examination, while a not negligible part
(34%) was not ultrasonographically suspicious (Figure 2).
As the main finding, a suspicious US presentation of MTC
conferred a 450% increase of risk of advanced TNM stages.
Furthermore, the presence of characteristics of higher
tumor aggressiveness was significantly more frequent in the
group with a “malignant” ultrasonographic presentation. In
addition, the value of serum calcitonin and before and after
surgery was significantly higher in m-MTC group. Present
data suggest that m-MTC behave as a more aggressive
tumor. As the first one, Fukushima et al [12] studied this
topic analyzing the prognosis of medullary thyroid cancer
in correlation with “benign” or “malignant” US presenta-
tion. That interesting series was collected over nineteen
years (1988–2007) and included only nonhereditary can-
cers. Of the 77 cases, 70% were malignant at US (“M-type”)
and 30% benign (“B-type”). The “B-type” MTC were highly
indolent tumors and had excellent prognosis with signifi-
cant postsurgical drop of both calcitonin; on the contrary,dule with calcifications, classified at ultrasonography as suspicious.
asonography.
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involvement, extrathyroid invasion and biochemical persist-
ence of disease. Here we used the same ultrasound risk
stratification adopted by Fukushima and colleagues [12],
and our results perfectly agree with that data. Furthermore,
present study explains the results reported by Fukushima et
al [12]. Based on both series, a preoperative ultrasound
examination should be performed in all MTC patients to
better tailor the surgical approach. In clinical practice these
data achieve high importance. In fact, MTC prognosis
depends on extent of disease at diagnosis, presence of re-
gional lymph node metastases, completeness of the surgical
resection and undetectable postsurgical calcitonin [1,23].
As a second objective, here we analyzed the US reliabil-
ity in diagnosing MTC lesions and our data might be
discussed in comparison to the previous reports [6-10]. In
all, these papers reported that a not negligible percentage
of MTC may be found with no ultrasound risk features. In
particular, characteristics of benignancy, such as round
shape, cystic changes, homogeneous echostructure, and
circumscribed margins, were often recorded in MTC.
More recently, these data confirm the previous experience
of one center of those participant to the present multicen-
ter study; there, MTC and PTC were compared with a large
benign control group, and MTC showed poor discrepancy
with respect to the controls [11]. Also, a heterogeneous
elastographic presentation was recently described [24].
Here we recorded that about one in three MTC nodules
manifests at ultrasonography as benign, being this finding
quite similar to that reported by Fukushima et al [12]. This
finding extends the conclusions of all the above studies
[6-12] and indirectly prompts to use calcitonin measure-
ment in the initial evaluation of thyroid nodules [2,4]. In
general, the possibility to submit to FNA all nodules with a
significant size (i.e. 1 cm) should be taken into account,
even if they have a “benign” US presentation.
The strength of this paper is the large sample size of
MTC and the multicenter design. Also, it has to be under-
lined that the series was collected in a recent period using
high resolution ultrasound systems which improved both
diagnosis and follow-up of several conditions [22,24-26].
To date, the knowledge on US presentation of MTC is
poor, and the present data strongly improve the literature
on this matter.
In conclusion, this study showed that MTC with preopera-
tive “at-risk” US presentation is more frequently associated
with features of tumor aggressiveness than those with no
suspicious ultrasonography. In clinical practice, these data
suggest a preoperative thyroid ultrasound assessment of
MTC patients to better plan their surgical approach. Further
prospective studies on this topic are necessary.Competing interests
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